Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults

Vaccine

Volumn 29, Issue 49, 2011, Pages 9224-9228

  Hatakeyama, Shuji ^a,b   Iwatsuki Horimoto, Kiyoko ^b   Okamoto, Koh ^a   Nukui, Yoko ^a   Yata, Nahoko ^d   Fujita, Akira ^e   Inaba, Shigeki ^f   Yotsuyanagi, Hiroshi ^a   Kawaoka, Yoshihiro ^b,c,g,h  

^a UNIVERSITY OF TOKYO   (Japan)

^b Division of Virology   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^e TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^f Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antibody response; Haemagglutinin inhibition; HIV; Immunogenicity; Influenza A (H1N1); Vaccine; Virus neutralization

Indexed keywords

INFLUENZA VACCINE; RNA;

ADULT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS NEUTRALIZATION;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4 LYMPHOCYTE COUNT; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RNA, VIRAL;

EID: 82555205313     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.106     Document Type: Article

References (24)

1. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
2. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
3. Cheong H.J., Song J.Y., Heo J.Y., Noh J.Y., Choi W.S., Park D.W., et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine 2011, 29:523-527.
4. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
5. Roman F., Vaman T., Kafeja F., Hanon E., Van Damme P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51:668-677.
6. Ikematsu H., Nagai H., Kawashima M., Kawakami Y., Tenjinbaru K., Maeda A., et al. Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccine 2010, 6:888-893.
7. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24:2187-2192.
8. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
9. Vigano A., Bedogni G., Giani E., Coletto S., Stucchi S., Pariani E., et al. Single and double doses of 2009 pandemic influenza A H1N1 vaccine are equally immunogenic in HIV-infected adolescents and young adults. 18th conference on retroviruses and opportunistic infections (CROI 2011) 2011, [abstract 729].
10. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
11. Tremblay C.L., Rouleau D., Fortin C., Toma E., Sylla M., Cyr L., et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 2011, 29:1359-1363.
12. Santini-Oliveira M., Camacho L., Souza T., Siqueira M., Giacoia-Gripp C., Nunes E., et al. Immunogenicity to an H1N1 adjuvanted influenza vaccine in HIV-infected adults: 2 single vs 2 double doses: the VIP-H1N1 study. 18th conference on retroviruses and opportunistic infections (CROI 2011) 2011, [abstract 910].
13. Orlando G., Pariani E., Mazza F., Tanzi E., Meraviglia P., Gianelli E., et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 2010, 24:2142-2143.
14. Fabbiani M., Di Giambenedetto S., Sali M., Farina S., Sansonetti P., Tamburrini E., et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011, 10.1016/j.vaccine.2011.02.020.
15. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52:122-127.
16. Soonawala D., Rimmelzwaan G.F., Gelinck L.B., Visser L.G., Kroon F.P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011, 6:e16496.
17. Cooper C., Klein M., Walmsley S., Hasse D., Scheifele D. A randomized trial to compare the immunogenicity and efficacy of adjuvanted pandemic H1N12009 vaccine with or without booster in HIV+ adults. 18th conference on retroviruses and opportunistic infections (CROI 2011) 2011, Publ Hlth Agency of Canada-Canadian Inst of Hlth Res Influenza Res Network, [abstract 907].
18. Calmy A., Bel M., Combescure C., Nguyen A., Yerly S., Kaiser L., et al. Impact of ASO3-adjuvanted pandemic influenza vaccines in HIV-infected and healthy adults. 18th conference on retroviruses and opportunistic infections (CROI 2011) 2011, [abstract 908].
19. Durier C., Desaint C., Colin de Verdière N., Girard P.-M., Lévy Y., Rey D., et al. Durability of the immune response after vaccination with 2 doses of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant in HIV+ adults: ANRS 151 randomized HIFLUVAC trial. 18th conference on retroviruses and opportunistic infections (CROI 2011) 2011, [abstract 909].
20. World Health Organization. WHO manual on animal influenza diagnosis and surveillance (WHO/CDS/CSR/NCS/2002.5). [accessed 21.03.11]. http://www.wpro.who.int/internet/resources.ashx/CSR/Publications/manual+on+animal+ai+diagnosis+and+surveillance.pdf.
21. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
22. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999, 28:541-547.
23. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Mühlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
24. Cooper C., Thorne A., Klein M., Conway B., Boivin G., Haase D., et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011, 6:e17758.